Refractory carcinoid syndrome: a review of treatment options.
作者： Rachel P. Riechelmann , Allan A. Pereira , Juliana F. M. Rego , Frederico P. Costa
关键词:
摘要: Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in patients with well differentiated neuroendocrine tumors (NETs), somatostatin analogs (SSAs) being the first-line option for symptom management. However, symptomatic progression eventually occurs and this scenario refractory CSy; several treatment options have been studied such as dose escalation SSA, interferon liver-directed therapies. Nevertheless, recent phase III trials contributed to understanding management condition. We performed comprehensive review interventional studies examining CSy provide evidence current propose sequence.
sagepub.com
sci-hub.se 参考文章(60)
G. Scarpelli, V. Ramundo, D. Ferone, P. Ferolla, G. Angeletti, A. Faggiano, L. M. Camera, F. Grimaldi, A. Colao, M. C. Bellucci, R. Severino, G. Lombardi, Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses Journal of Endocrinological Investigation. ,vol. 35, pp. 326- 331 ,(2011) , 10.3275/7869
Jonathan R. Strosberg, Junsung Choi, Alan B. Cantor, Larry K. Kvols, Selective Hepatic Artery Embolization for Treatment of Patients With Metastatic Carcinoid and Pancreatic Endocrine Tumors Cancer Control. ,vol. 13, pp. 72- 78 ,(2006) , 10.1177/107327480601300110
Seong-Jang Kim, Kyoungjune Pak, Phillip J. Koo, Jennifer J. Kwak, Samuel Chang, The efficacy of 177 Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 1964- 1970 ,(2015) , 10.1007/S00259-015-3155-X
Hannah E. Bainbridge, Emmanuel Larbi, Gary Middleton, Symptomatic Control of Neuroendocrine Tumours with Everolimus Hormones and Cancer. ,vol. 6, pp. 254- 259 ,(2015) , 10.1007/S12672-015-0233-2
Georgios Boutzios, Gregory Kaltsas, Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms Frontiers of Hormone Research. ,vol. 44, pp. 40- 57 ,(2015) , 10.1159/000382053
Edward Wolin, Barbara Jarzab, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Jiang Li, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell-Price, Wasat Mansoor, Kjell Öberg, Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues Drug Design Development and Therapy. ,vol. 9, pp. 5075- 5086 ,(2015) , 10.2147/DDDT.S84177
Jonathan Strosberg, Jamie Goldman, Frederico Costa, Marianne Pavel, The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Frontiers of Hormone Research. ,vol. 44, pp. 239- 247 ,(2015) , 10.1159/000403785
John Eriksson, Peter Stålberg, Anders Nilsson, Johan Krause, Christina Lundberg, Britt Skogseid, Dan Granberg, Barbro Eriksson, Göran Åkerström, Per Hellman, Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors World Journal of Surgery. ,vol. 32, pp. 930- 938 ,(2008) , 10.1007/S00268-008-9510-3
J. Philip Boudreaux, Yi-Zarn Wang, Anne E. Diebold, Daniel J. Frey, Lowell Anthony, Ann Porter Uhlhorn, Pamela Ryan, Eugene A. Woltering, A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors. Journal of The American College of Surgeons. ,vol. 218, pp. 837- 844 ,(2014) , 10.1016/J.JAMCOLLSURG.2013.12.035
Herbert A. Schmid, Pasireotide (SOM230): Development, mechanism of action and potential applications Molecular and Cellular Endocrinology. ,vol. 286, pp. 69- 74 ,(2008) , 10.1016/J.MCE.2007.09.006